The Australian stock market has recently experienced a notable upswing, with the ASX gaining 1.3% amid strong performances in sectors like Materials and Healthcare, driven by global economic factors such as uncertainty around a potential U.S. government shutdown. In this buoyant environment, growth companies with high insider ownership can be particularly appealing to investors, as they often indicate confidence from those closest to the business and may align well with current market trends favoring robust sectoral gains.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Wisr (ASX:WZR) | 12.1% | 91.2% |
| Titomic (ASX:TTT) | 11.3% | 74.9% |
| Pointerra (ASX:3DP) | 23.4% | 110.3% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| Gratifii (ASX:GTI) | 17.8% | 137.7% |
| Findi (ASX:FND) | 33.6% | 91.2% |
| Emerald Resources (ASX:EMR) | 18.1% | 38.3% |
| Echo IQ (ASX:EIQ) | 17.9% | 49.9% |
| Adveritas (ASX:AV1) | 18.8% | 96.8% |
| Acrux (ASX:ACR) | 15.1% | 121.1% |
Here we highlight a subset of our preferred stocks from the screener.
Clinuvel Pharmaceuticals (ASX:CUV)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$606.99 million.
Operations: The company's revenue is primarily generated from its Biopharmaceutical Sector, amounting to A$95.02 million.
Insider Ownership: 10.3%
Clinuvel Pharmaceuticals showcases strong growth potential, with revenue forecasted to increase by 22% annually, outpacing the Australian market. Earnings are also expected to grow significantly at 26.2% per year. Despite trading at a substantial discount to its estimated fair value, Clinuvel's Return on Equity is projected to be modest in three years. Recent earnings showed a slight increase in net income and revenue compared to the previous year, reflecting ongoing operational progress.
- Navigate through the intricacies of Clinuvel Pharmaceuticals with our comprehensive analyst estimates report here.
- The valuation report we've compiled suggests that Clinuvel Pharmaceuticals' current price could be quite moderate.
Develop Global (ASX:DVP)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Develop Global Limited, with a market cap of A$1.44 billion, is involved in the exploration and development of mineral resource properties in Australia through its subsidiaries.
Operations: The company's revenue is primarily derived from its Mining Services segment, which accounts for A$240.65 million, supplemented by A$14.63 million from Mining and Exploration activities.
Insider Ownership: 20.2%
Develop Global demonstrates robust growth prospects with revenue expected to grow at 32.5% annually, significantly outpacing the Australian market. Earnings are projected to rise by 20.46% per year, indicating substantial growth potential. The company recently reported a net income of A$72.39 million for the full year, reversing a previous loss, and achieved profitability this year. Despite past shareholder dilution and a forecasted low Return on Equity of 14%, Develop Global remains competitively valued with its Price-To-Earnings ratio below the market average.
- Dive into the specifics of Develop Global here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential overvaluation of Develop Global shares in the market.
Regis Healthcare (ASX:REG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$1.94 billion.
Operations: The company generates revenue of A$1.16 billion from its residential aged care, home care, and retirement living services in Australia.
Insider Ownership: 38.6%
Regis Healthcare shows promising growth potential with revenue forecasted to increase by 7.7% annually, outpacing the broader Australian market. The company turned profitable this year, reporting a net income of A$48.95 million, and earnings are expected to grow at 18.6% per year, faster than the market average. Despite trading significantly below its estimated fair value and experiencing substantial insider selling recently, Regis maintains a high Return on Equity forecast and analysts anticipate a price rise of 24%.
- Click here to discover the nuances of Regis Healthcare with our detailed analytical future growth report.
- Insights from our recent valuation report point to the potential undervaluation of Regis Healthcare shares in the market.
Taking Advantage
- Unlock more gems! Our Fast Growing ASX Companies With High Insider Ownership screener has unearthed 106 more companies for you to explore.Click here to unveil our expertly curated list of 109 Fast Growing ASX Companies With High Insider Ownership.
- Contemplating Other Strategies? Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Clinuvel Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com